Connect your AI

Alkermes ALKS Change in Other Liabilities

Change in Other Liabilities at other companies

Jazz PharmaceuticalsJAZZ

$12.2M+321%

Ionis PharmaceuticalsIONS

$21M+6,207%

BridgeBio PharmaBBIO

$4.62M+56.8%

BiogenBIIB

-$62M-38.8%

TG TherapeuticsTGTX

-$1.62M+12.8%

LQD

Liquidia CorporationLQDA

——

Other financials

Income statement

Revenue$392.9M+28.2%

Gross profit$331.3M+28.8%

Operating income-$48.3M-450%

Net income-$66.5M-396%

EPS (diluted)-$0.40-408%

Balance sheet

Cash & equivalents$351.6M-12.1%

Total debt$1.6B+2,034%

Total equity$1.8B+15.9%

Total assets$4.3B+105%

Cash flow

Operating cash flow-$165.7M-268%

CapEx$4.1M-59.5%

Free cash flow-$169.8M-291%

Valuation

Market cap$7.5B+9.7%

Enterprise value$8.73B+41.2%

P/E49.1×+29.7×

P/S4.8×+0.3×

Profitability

Gross margin86.6%+2.2pp

Operating margin12.3%-13.6pp

Net margin9.8%-13.5pp

FCF margin14.2%-17.6pp

Returns & leverage

Return on equity9.4%-16.1pp

Debt / equity0.9×+0.9×

Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.

The official record: Alkermes’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alkermes's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Alkermes's change in other liabilities?: Alkermes (ALKS) reported change in other liabilities of $4.89M in Q1 2026.
How has Alkermes's change in other liabilities changed year-over-year?: Alkermes's change in other liabilities increased by 71.5% year-over-year, from $2.85M to $4.89M.
What does change in other liabilities mean?: Change in miscellaneous liabilities affecting operating cash flow.